Author: Daniel A. Saez, MSc, Manager, LungMATCH Navigation Program For many years, the treatment options given to patients diagnosed with early stage non-small cell lung cancer (NSCLC) was limited to surgery with or without chemotherapy to improve outcomes. However, [...]
GO2 for Lung Cancer recognized Dr. Rafael Rosell at the 23rd International Lung Cancer Congress for his global contributions to oncology, particularly in the field of non-small-cell lung cancer (San Carlos, CA and Washington, DC) – GO2 for Lung [...]
Authors: Andrew Ciupek, PhD, Associate Director, Clinical Research and Daniel A. Saez, MSc, Manager, LungMATCH Navigation Program People who are diagnosed with early stage (stage 1-2) non-small cell lung cancer (NSCLC) are generally broken down into two groups: those [...]
On March 4th, 2022, the Food and Drug Administration (FDA) approved Opdivo (nivolumab) for treatment before surgery in combination with platinum-based chemotherapy in patients with stage IB to IIIA non-small cell lung cancer (NSCLC). The approval was based on [...]
Dan and Brittany Wilson were high school sweethearts. Now, 20 years later, they're married with two young daughters (ages five and seven). When Dan was diagnosed in February 2019 with stage 4A non-small cell Lung cancer, they turned to [...]
Author: Rashmi Acharya, MS, Science and Research Specialist, GO2 for Lung Cancer The 2021 World Conference on Lung Cancer (WCLC) had multiple researchers presenting their findings on broad areas of research in early-stage lung cancer. These presentations bring highly [...]
On September 15th, 2021, the Food and Drug Administration (FDA) approved Exkivity (mobocertinib) for treatment of advanced non-small cell lung cancer (NSCLC) with a change in EGFR called exon 20 insertion. The FDA based their approval on the results [...]
By Jennifer C. King, PhD, Chief Scientific Officer, GO2 for Lung Cancer Surgery has been the primary treatment for early stage non-small cell lung cancer (NSCLC). Unfortunately, many people have seen their cancer come back after surgery. Now researchers [...]
By Andrew Ciupek, PhD, Senior Manager, Clinical Research, GO2 for Lung CancerA number of studies presented at the American Society of Clinical Oncology’s (ASCO) Annual Meeting related to the treatment of non-small cell lung cancer (NSCLC) with an EGFR mutation.Tagrisso [...]
By Rashmi Acharya, MS, Coordinator, Science & Research, GO2 for Lung CancerChemotherapy has been the standard treatment option for Non-Small Cell Lung Cancer (NSCLC) without actionable biomarkers. Recently, immunotherapy treatments have been added into the treatment mix. Several studies presented [...]